Utang jangka cendhak perusahaan: Creative Medical Technology Holdings, Inc. (CELZ)

CELZ develops urological stem cell treatments, relying on copyright protection for profit. The stock price trend shown in the graph is 0.00. StemSpine and Stem體's safety has earned them a high reputation among physicians, while strict FDA regulation and patent barriers limit new players' entry into this sector.

The development of the StemSpine platform and expansion through urological centers require significant working capital, which is reflected in the structure of current liabilities. The total amount of short-term debt aggregates all financial obligations maturing within one year, allowing investors to assess the liquidity of Creative Medical Technology (CELZ) and the company's ability to service urgent loans under strict FDA oversight via the chart's dynamics.